Q2 2025 Camurus AB Earnings Call Transcript
Key Points
- Camurus AB (CAMRF) achieved record revenues in Q2 2025, with a 52% growth compared to the same period last year.
- The company entered a strategically important license agreement with Eli Lilly for long-acting incretins, enhancing its position in the cardiometabolic space.
- EU approval of Oczyesa for acromegaly treatment was a significant milestone, marking the first product based on Camurus' Crystal technology.
- Positive results were reported from the POSITANO study and ACROINNOVA extension trials, indicating strong R&D progress.
- Camurus maintained a strong cash position of SEK3.35 billion, providing financial stability for future expansions and investments.
- Product sales declined by 3% compared to the prior quarter, impacted by the appreciation of the Swedish krona.
- The royalty income from Brixadi sales in the US was negatively affected by currency fluctuations, reducing reported figures by 11 points.
- There was a short-term delay in committed funding reaching clinics in the UK, affecting Buvidal sales.
- The reimbursement situation in Germany remains challenging, impacting market penetration.
- The upfront payment from the Eli Lilly deal was considered small compared to other deals in the space, raising questions about the financial structure.
Welcome to Camurus Q2 report 2025. (Operator Instructions)
Now, I will hand the conference over to CEO, Fredrik Tiberg. Please go ahead.
Thank you, Einar, and hello, everyone. Welcome to our second-quarter earnings call. Here are our forward-looking statements.
So the agenda for our call today is a summary of highlights in the quarter, followed by financial and commercial performance reviews, then an update on the pipeline and business development before finishing up with Q&A. So with me to provide the financial update is Jon Garay, CFO. Also present are Richard Jameson, Chief Commercial Officer; and Anders Vadsholt, incoming CFO.
So Camurus had a successful second quarter with good performances across our business. Financially, we delivered all-time record revenues, high profitability, further strengthening our cash position for planned expansions and pipeline investments.
And on the corporate side, we entered a strategically
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
